1. Kadiyala GN, Telwatte S, Wedrychowski A, Janssens J, et al.
   Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules.
   AIDS 2024.
   


2. Alhammadi A, Alshawaf R, Chavda S, Ramondino S, et al.
   Infectious Diseases: What You May Have Missed in 2023.
   Ann Intern Med 2024.
   


3. Coyle RP, Morrow M, Mann SC, Mainella V, et al.
   Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
   Clin Infect Dis 2024.
   


4. Bachelard A, Le Hingrat Q, Ferre VM, Le M, et al.
   Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
   Clin Infect Dis 2024;78:1005-1010.
   


5. Mutetwa T, Liu Y, Silvera R, Evans M, et al.
   Host Nuclear Genome Copy Number Variations Identify High-Risk Anal Precancers in People Living with HIV.
   J Acquir Immune Defic Syndr 2024.
   


6. Murenzi G, Kim HY, Mivumbi JP, Gasana J, et al.
   Incidence, Clearance and Persistence of Penile High-Risk Human Papillomavirus among Rwandan Men who have Sex with Men.
   J Infect Dis 2024.
   


7. Begre L, Boyd A, Plissonnier ML, Testoni B, et al.
   Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
   J Infect Dis 2024.
   


8. Matusali G, Vergori A, Cimini E, Mariotti D, et al.
   Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
   J Med Virol 2024;96:e29598.
   

Display articles in

• Abstract format
• Medline format